NAMPT inhibitor-based ADC (Seattle Genetics)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameNAMPT inhibitor-based ADC (Seattle Genetics)
Drug Alias Nameantibody-drug conjugates (Seattle Genetics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionNicotinamide phosphoribosyltransferase inhibitors
TargetsNicotinamide phosphoribosyltransferase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeagen Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A